(Q44356218)

2 December 2017

title

Evaluation of the clinical and economic impact of a brand name-to-generic warfarin sodium conversion program (English)

1 reference

2 December 2017

1 reference

Daniel M Witt

1

1 reference

2 December 2017

Donald J Tillman

2

1 reference

2 December 2017

Christy M Evans

3

1 reference

2 December 2017

Tatyana V Plotkin

4

1 reference

2 December 2017

Melanie A Sadler

5

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

2 December 2017

1 reference

2 December 2017

volume

23

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

360-368

1 reference

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.3.360.32103

Subtherapeutic INR values associated with a switch to generic warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.3.360.32103

A randomized, crossover comparison of warfarin products in the treatment of chronic atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.3.360.32103

Substitution of generic warfarin for Coumadin in an HMO setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.3.360.32103

Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.3.360.32103

10.1592/PHCO.23.3.360.32103

21 January 2018

Identifiers

DOI

1 reference

2 December 2017

1 reference